GlassScriptPhysician profile
Paula A Gustafson
NPI 1770511305
$3,319.71
in general payments reported to CMS, 2019-2025
26 companies · $406 in 2025
The $406 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $148 · 2021: $301 · 2022: $342 · 2023: $718 · 2024: $1,099 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,126.02 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,144.07 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Supernus Pharmaceuticals, INC. | $616.71 | 2021-2024 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $260.20 | 2019-2024 | Arexvy, Bexsero, Pediarix |
| Ironshore Pharmaceuticals INC. | $244.59 | 2019-2024 | Jornay Pm |
| Corium, LLC | $170.31 | 2022-2025 | Azstarys |
| Tris Pharma INC | $164.32 | 2019-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $132.28 | 2019-2022 | |
| Pfizer INC. | $125.40 | 2023-2025 | |
| Corcept Therapeutics | $77.30 | 2021-2025 | Korlym |
| Cranial Technologies, INC | $43.62 | 2023-2025 | Doc Band |
| Madrigal Pharmaceuticals | $35.35 | 2024 | Resmetirom |
| Sanofi Pasteur INC. | $33.31 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $33.28 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $24.85 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.49 | 2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $22.63 | 2024 | Xelstrym |
| Bayer Healthcare Pharmaceuticals INC. | $21.88 | 2024 | |
| Neos Therapeutics, LP | $19.03 | 2019 | |
| Sobi, INC | $18.75 | 2019 | |
| Kyowa Kirin, INC. | $18.48 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.29 | 2024 | Crysvita |
| Verrica Pharmaceuticals INC. | $16.84 | 2024 | Ycanth |
| Amneal Pharmaceuticals LLC | $16.64 | 2020 | |
| Boston Scientific Corporation | $14.20 | 2019 | |
| Shire North American Group INC | $12.73 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Gustafson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.